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The multidrug resistance proteins P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and
multidrug resistance-associated protein 2 (Mrp2) are the three major canalicular transport proteins respon-
sible for the biliary excretion of most drugs and metabolites. Previous in vitro studies demonstrated that P-gp
transported macrolide antibiotics, including spiramycin, which is eliminated primarily by biliary excretion.
Bcrp was proposed to be the primary pathway for spiramycin secretion into breast milk. In the present study,
the contributions of P-gp, Bcrp, and Mrp2 to the biliary excretion of spiramycin were examined in single-pass
perfused livers of male C57BL/6 wild-type, Bcrp-knockout, and Mrp2-knockout mice in the presence or absence
of GF120918 (GW918), a P-gp and Bcrp inhibitor. Spiramycin was infused to achieve steady-state conditions,
followed by a washout period, and parameters governing spiramycin hepatobiliary disposition were recovered
by using pharmacokinetic modeling. In the absence of GW918, the rate constant governing spiramycin biliary
excretion was decreased in Mrp2 knockout mice (0.0013  0.0009 min1) relative to wild-type mice (0.0124 
0.0096 min1). These data are consistent with the 8-fold decrease in the recovery of spiramycin in the bile
of Mrp2-knockout mice and suggest that Mrp2 is the major canalicular transport protein responsible for
spiramycin biliary excretion. Interestingly, biliary recovery of spiramycin in Bcrp-knockout mice was increased
in both the absence and presence of GW918 compared to wild-type mice. GW918 significantly decreased the
rate constant for spiramycin biliary excretion and the rate constant for basolateral efflux of spiramycin. In
conclusion, the biliary excretion of spiramycin in mice is mediated primarily by Mrp2 with a modest P-gp
component.
Spiramycin is used to treat respiratory infections (8, 17).
Although spiramycin is associated with fewer severe adverse
reactions than other macrolide antibiotics (e.g., erythromycin)
(17), cases of spiramycin-induced cholestatic hepatitis and liver
injury have been reported (4, 18). The systemic clearance of
spiramycin is 1.14  0.27 liters/min in humans (5); renal clear-
ance of spiramycin in humans is low (0.144  0.047 liters/min)
relative to nonrenal clearance (0.887  0.096 liters/min) (5).
Spiramycin is not extensively metabolized, and biliary excre-
tion is the primary route of spiramycin elimination (2, 7).
Biliary excretion of xenobiotics is mediated primarily by
ATP-dependent transport proteins located on the canalicular
membrane of hepatocytes, namely, P-glycoprotein (P-gp, en-
coded by Abcb1), breast cancer resistance protein (Bcrp, en-
coded by Abcg2), and multidrug resistance-associated protein 2
(Mrp2, encoded by Abcc2) (3). Intracellular accumulation of
spiramycin was reduced in murine fibroblast cells transfected
with the human MDR1 gene (15); cellular concentrations of
spiramycin in MDR1-transfected cells were one-third of that
observed in nontransfected cells. Although spiramycin exhibits
high penetration into many tissues, it is undetectable in rat or
monkey brain (21, 23), which implies that P-gp, Bcrp, or pos-
sibly Mrp2 limits spiramycin central nervous system exposure
(6, 12).
Given the importance of biliary clearance in the elimination
of spiramycin, the present study was designed to elucidate the
roles of canalicular transport proteins mediating spiramycin
biliary excretion.
MATERIALS AND METHODS
Chemicals. Spiramycin and rosamicin were purchased from Sigma-Aldrich
(St. Louis, MO). Spiramycin was a mixture of spiramycin I (92.6%), II (0.4%),
and III (1.1%). Rosamicin had a purity of 98%. The P-gp and Bcrp inhibitor
GF120918, N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-
phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide] (abbreviated
as GW918), was a gift from GlaxoSmithKline (Research Triangle Park, NC).
All other reagents were of analytical grade and were readily available from
commercial sources.
Animals. Male C57BL/6 (wild-type), Abcc2/ (Mrp2-knockout), and
Abcg2/ (Bcrp-knockout) (abbreviated B6, Mrp2KO, and BcrpKO, respec-
tively) mice (24 to 27 g) were gifts from Eli Lilly and Company. Further details
regarding the background, generation, and breeding of these mice have been
described by Nezasa et al. (14). Mice were housed in an alternating 12-h light-
dark cycle with free access to rodent chow and water. All of the animal proce-
dures were approved by The Institutional Animal Care and Use Committee at
the University of North Carolina at Chapel Hill.
Single-pass liver perfusion. Briefly, mice were anesthetized with ketamine and
xylazine (140 and 8 mg/kg given intraperitoneally) and maintained at 37°C. The
gallbladder was cannulated with PE-10 tubing. The portal vein and inferior vena
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cava between the liver and the heart were cannulated with a 20G catheter, and
the inferior vena cava below the liver was ligated between the kidney and the
liver. The liver was perfused in situ in a single-pass manner via the portal vein
with Krebs-Henseleit buffer containing 5 M taurocholate (5-ml/min flow rate,
37°C, buffer saturated with 95% O2 and 5% CO2). The liver was allowed to
equilibrate during the 15-min preperfusion period. Subsequently, the liver was
perfused for 15 min to achieve steady-state conditions with buffer containing 1
M spiramycin and 10 M GW918 or vehicle (dimethyl sulfoxide), followed by
a 25-min washout phase during which the liver was perfused with blank buffer.
Perfusate outflow was collected in toto at designated time points throughout the
40-min experiment. Bile was collected in toto at 7-min intervals.
Sample analysis. To prepare samples for analysis, perfusate and bile were
diluted 11- and 250-fold, respectively, with methanol-water (50:50 [vol/vol]).
Rosamicin was used as the internal standard. Spiramycin and rosamicin concen-
trations were quantified by reversed-phase high performance liquid chromatog-
raphy with detection by tandem mass spectrometry (Applied Biosystems API
4000 triple quadrupole with Turbo-IonSpray interface; MDS Sciex, Foster City,
CA). After a 10-l sample injection, analytes were eluted from an Aquasil
column (C18, 5 m, 50 by 2.1 mm; Thermo Electron, Bellafonte, PA) using the
following gradient (mobile phase A  1% formic acid in water; mobile phase
B  1% formic acid in methanol): for 0 to 0.8 min, hold at 30% mobile phase B;
for 0.8 to 3.5 min, linear gradient to 85% mobile phase B; for 3.5 to 4 min, hold
at 85% mobile phase B; for 4 to 4.1 min, linear gradient to 30% mobile phase B;
for 4.1 to 5 min, hold at 30% mobile phase B, with a flow rate of 0.75 ml/min; and
for 0.8 to 5 min directed to mass spectrometer. Spiramycin (m/z 843.63540.4)
and rosamicin (m/z 582.43158.1) were detected in positive ion mode by using
multiple reaction monitoring. Consistent with a previous report (19), the spira-
mycin was stable when stored at 4°C, and assay variations were within acceptable
ranges (within 18% for bile samples and 13% for perfusate samples) with a
lower limit of quantitation of 10 ng/ml.
Pharmacokinetic modeling. Compartmental modeling by nonlinear least squares
regression was used to characterize the hepatobiliary disposition of spiramycin in
perfused livers. Various two- and three-compartment models were developed to
describe the spiramycin outflow perfusate rate and biliary excretion rate data. The
goodness of fit of each model was evaluated based on visual inspection, residual
distribution, coefficients of variation on the parameter estimates, the condition
number, and Akaike’s information criterion (1). The compartment model that best
described the data is shown in Fig. 1. The first liver compartment (L1) represented
the hepatocellular space, which quickly equilibrates with perfusate. The second (L2)
and third (L3) liver compartments were used to describe the hepatocellular distri-
bution and sequestration of spiramycin. Metabolism was assumed not to occur (2, 8).
Differential equations derived from the model scheme in Fig. 1 were as follows:
dXL1/dt  CLup  Cin  Kps  XL1  K12  XL1  K21  XL2  K13  XL1
 K31  XL3; XL10  0; t  15 min
dXL1/dt  Kps  XL1  K12  XL1  K21  XL2  K13  XL1  K31  XL3;
t  15 min
dXL2/dt  K12  XL1  K21  XL2  Kb  XL2; XL20  0
dXL3/dt  K13  XL1  K31  XL3; XL30  0
dXperfusate/dt  Q  Cin  CLup  Cin  Kps  XL1; t  15 min
dXperfusate/dt  Kps  XL1; t  15 min
dXbite/dt  Kb  XL2
where CLup is the hepatic uptake clearance, Kps is the first-order rate constant
governing the basolateral excretion of spiramycin from the liver back into per-
fusate, Kb is the first-order rate constant governing the biliary excretion of
spiramycin, and Kij represents the first-order rate constant governing the move-
ment of spiramycin between liver compartments “i” and “j”, respectively; and XLi
represents the mass of spiramycin in liver compartment “Li”. Xperfusate and Xbile
represent the mass of spiramycin in perfusate and bile, respectively. Simulations
of cumulative biliary excretion profiles were conducted.
Data analysis. All data are reported as mean  standard deviation (SD) (n 
three animals per group). Statistical significance (P  0.05) was assessed on raw
or log-transformed data, as appropriate to address unequal variance, by two-way
analysis of variance with mouse type (Mrp2KO, BcrpKO, or B6) and treatment
(vehicle or GW918) as the independent variables.
RESULTS
Recovery of spiramycin. The total percent recoveries of spi-
ramycin in outflow perfusate and bile at the end of the liver
perfusion were 90.5%  11.7%, 82.4%  12.6%, and 86.5% 
15.8% of the dose for B6, Mrp2KO, and BcrpKO mice, re-
spectively. There were no significant differences in the total
recoveries of spiramycin in B6, Mrp2KO, and BcrpKO mice.
The total recovery of spiramycin was not significantly altered by
coinfusion of GW918. Spiramycin was concentrated in the bile of
B6 and BcrpKO mice. The maximum spiramycin concentrations
in bile were 8.65  3.43, 3.45  2.15, and 19.1  2.6 g/ml,
respectively, in control B6, Mrp2KO, and BcrpKO mice; during
coinfusion of GW918, the maximum spiramycin concentrations in
bile were 7.82  9.12, 1.77  0.74, and 14.0  5.8 g/ml, respec-
tively. In the absence of GW918, the recovery of spiramycin in the
bile of Mrp2KO mice was 19 and 12% of that in B6 and BcrpKO
mice, respectively. In the presence of GW918, the recovery of
spiramycin in the bile of Mrp2KO mice was 17 and 10% of that
in B6 and BcrpKO mice, respectively.
Cumulative excretion of spiramycin in perfusate and bile
during the washout phase was analyzed and expressed as a
percentage of spiramycin liver content after the 15-min infu-
sion of spiramycin (Table 1). Cumulative biliary excretion of
spiramycin decreased 8-fold in Mrp2KO and increased ap-
proximately 54% in BcrpKO mice compared to B6 mice (Table
1). GW918 significantly decreased the cumulative amount of
spiramycin recovered in bile during the 25-min washout phase
(Table 1).
FIG. 1. Model scheme depicting spiramycin disposition in the
single-pass perfused liver. Q, flow rate; Cin, concentration of spira-
mycin in inflow perfusate; Cout, concentration of spiramycin in
outflow perfusate; CLup, uptake clearance into the liver; Kps, first-
order rate constant for basolateral excretion; XL1, XL2, and XL3,
amount of spiramycin in liver compartments 1, 2, and 3, respec-
tively; K12 and K21, first-order rate constants for distribution be-
tween liver compartments 1 and 2, respectively; K13 and K31, first-
order rate constants for distribution between liver compartments 1
and 3, respectively; Kb, first-order rate constant for biliary excre-
tion; Xbile, amount of spiramycin in bile.
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Pharmacokinetic modeling and simulations. The model
scheme depicted in Fig. 1 best described the data. Represen-
tative fits of the model to spiramycin biliary excretion rate and
outflow perfusate rate versus time data are shown in Fig. 2.
Pharmacokinetic parameter estimates are reported in Table 1.
The uptake clearance (CLup) approximated the perfusate flow
rate (5 ml/min). The basolateral efflux rate constant (Kps) was
not altered by knockout of Mrp2 or Bcrp but was significantly
decreased by GW918. The biliary excretion rate constant (Kb)
was decreased in knockout relative to wild-type mice. In the
absence of GW918, Kb in Mrp2KO mice was decreased 10-fold
compared to B6 mice (0.0124  0.0096 min1 versus 0.0013 
0.0009 min1). Although the biliary excretion rate constant in
BcrpKO mice was highly variable, it was 2-fold that in B6
mice (0.0124  0.0096 min1 versus 0.0270  0.0153 min1).
GW918 decreased the biliary excretion rate constant. Based on
simulations, the pharmacokinetic model accurately described
the biliary excretion of spiramycin (Fig. 3). No statistically
significant differences were observed in intercompartmental
rate constants between the perfused livers from wild-type and
knockout mice in the absence or presence of GW918.
DISCUSSION
Previous pharmacokinetic studies indicated that biliary ex-
cretion is the major route of spiramycin elimination (2). Three
major canalicular transport proteins (P-gp, Bcrp, and Mrp2)
have been implicated in the biliary transport of spiramycin (6,
10, 12, 15, 21). Elucidation of the transport proteins mediating
spiramycin biliary excretion is important for the prediction of
potential spiramycin-related drug-drug interactions and may
contribute to our understanding of the mechanisms of biliary
excretion of related macrolide antibiotics.
The importance of Mrp2 in the biliary excretion of organic
anions is well documented in Mrp2-deficient rats, Mrp2KO
mice, and humans with Dubin-Johnson syndrome (9, 16). In
the present study, knockout of Mrp2 caused a 10-fold decrease
in the rate constant governing spiramycin biliary excretion,
which clearly demonstrated that Mrp2 is the major transport
protein responsible for the canalicular excretion of spiramycin
into bile. Individuals with impaired Mrp2 function may be
susceptible to spiramycin-induced liver injury. Cases of spira-
mycin-induced cholestatic hepatitis and liver injury have been
reported (4, 18); elevated bilirubin levels were observed in
these patients.
Bcrp was identified as an antibiotic transporter by using
transfected cell lines and BcrpKO mice (13). Unlike Mrp2 and
P-gp, Bcrp can transport nitrofurantoin with high efficiency,
and the biliary excretion of nitrofurantoin was negligible in
BcrpKO mice (13). Milk concentrations of nitrofurantoin were
decreased 80-fold in BcrpKO mice; it was postulated that spi-
TABLE 1. Spiramycin recovery in perfusate and bile and pharmacokinetic parameter estimates governing spiramycin disposition in single-
pass perfused livers from B6, Mrp2KO, and BcrpKO micea
Parameter B6 Mrp2KO BcrpKO
Spiramycin recovery (% of liver
content at end of infusion)
Perfusate
Vehicle 32.5  4.8 29.5  6.0 28.1  5.6
GW918 34.1  4.5 24.0  4.8 25.2  2.3
Bileb,c
Vehicle 9.15  4.15 1.21  1.23 14.1  2.0
GW918 4.36  0.48 0.58  0.26 8.28  0.80
Pharmacokinetic parameter estimates
CLup (ml/min)
Vehicle 4.63  0.37 5.15  0.23 4.55  0.44
GW918 4.64  0.20 4.70  0.14 5.03  0.05
Kps (min
1)c
Vehicle 0.488  0.178 0.420  0.079 0.453  0.047
GW918 0.317  0.041 0.373  0.034 0.311  0.014
K12 (min
1)
Vehicle 0.0427  0.0151 0.0501  0.0317 0.0441  0.0200
GW918 0.0240  0.0110 0.0410  0.0080 0.0209  0.0040
K21 (min
1)
Vehicle 0.1021  0.0380 0.1434  0.1261 0.1261  0.0431
GW918 0.1012  0.0407 0.0679  0.0240 0.0933  0.0100
Kb(min
1)b,c
Vehicle 0.0124  0.0096 0.0013  0.0009 0.0270  0.0153
GW918 0.0106  0.0011 0.0004  0.0001 0.0183  0.0054
K13 (min
1)
Vehicle 0.1066  0.0618 0.2064  0.0894 0.1669  0.0781
GW918 0.1457  0.0253 0.2123  0.0674 0.2021  0.0113
K31 (min
1)
Vehicle 0.0009  0.0001 0.0001 0.0022  0.0013
GW918 0.0007  0.0012 0.0001 0.0007  0.0002
a Values are mean  SD (n  3 per group).
b P  0.05, among mouse groups.
c P  0.05, GW918 vs vehicle.
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ramycin is a Bcrp substrate based on its high milk/plasma
concentration ratio in mice (10). Surprisingly, BcrpKO mice
did not exhibit a decrease in the biliary excretion rate constant
of spiramycin compared to wild-type mice. On the contrary,
the average biliary excretion rate constant of spiramycin in
BcrpKO mice was 2-fold higher than in B6 mice in the
present study, suggesting that knockout of Bcrp might have
indirectly altered the hepatobiliary disposition of spiramycin.
This phenomenon also was observed in our previous study in
which the biliary excretion of the Mrp2 probe substrate 5(and
6)-carboxy-2	,7	-dichlorofluorescein was significantly increased
in BcrpKO mice (14). This increase may be due to stimulation of
Mrp2 activity because of the accumulation of Bcrp substrates in
the hepatocytes of these knockout mice and/or to increased traf-
ficking of Mrp2 to the canalicular membrane (14).
P-gp was the first mammalian protein identified that trans-
ported macrolide antibiotics (20, 22, 24), including spiramycin,
in MDR1-expressing cell lines (15). Although GW918 signifi-
cantly decreased the biliary excretion of spiramycin, based on
our present observations, the role of P-gp in the biliary excre-
tion of spiramycin is modest compared to Mrp2. Interestingly,
GW918 significantly decreased the rate constant for basolat-
eral efflux of spiramycin consistent with a previous report that
GW918 inhibited the basolateral excretion of the opioid pep-
tide [D-Pen2,D-Pen5]-enkephalin (11).
FIG. 2. Representative fit of the compartmental model (Fig. 1) to spiramycin outflow perfusate rate (E, ng/min) and biliary excretion rate (F,
ng/min/g liver) data.
FIG. 3. Cumulative biliary excretion of spiramycin in mice (‚, B6;
Œ, B6GW918; E, Mrp2KO; F, Mrp2KOGW918; , BcrpKO; f,
BcrpKOGW918). Symbols represent means  the SD (n  three
animals per group). Lines represent the simulation of cumulative bil-
iary excretion of spiramycin (in nanograms) with the compartmental
model (Fig. 1) and mean parameter estimates (Table 1).
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Collectively, multiple transport systems are involved in the
biliary clearance of spiramycin in mice. Mrp2 is the major
transport protein responsible for the biliary excretion of spira-
mycin; P-gp serves as a backup transport system in the absence
of Mrp2. Bcrp may exert an indirect influence on the biliary
excretion of spiramycin.
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